Session XVIII: Immune Mechanisms and Microbiome in GI Tumors

Chair(s)

• 

  Sara De Dosso, MD

  Medical Oncology Department, Oncology Institute of Southern Switzerland
  Bellinzona, Switzerland
• 

  Josep Tabernero, MD

  Vall d’Hebron University Hospital
  Barcelona, Spain

Presentations:

• 17:15 – 17:23 CEST

  SO-22: Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the AtezoTRIBE study
  

  Abstract Presenter: Federica Marmorino
• 17:23 – 17:31 CEST

  SO-23: The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer
  

  Abstract Presenter: Rachel Purcell
• 17:31 – 18:00 CEST

  Microbiome and Colorectal Cancer
  

  Speaker: Elena Elez, Sr., MD PhD – Vall Hebron University Hospital
• 18:00 – 18:10 CEST

  LBA-4: Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
  

  Abstract Presenter: Andrea Bullock
• 18:10 – 18:30 CEST

  Resistance Factors to IOs
  

  Speaker: Guillem Argiles, MD – Memorial Sloan Kettering Cancer Center